®th IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44 Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California. Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section ...

IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, today announced that Providence Swedish Cancer Institute and the institute's focused translational research extension, the Paul G. Allen Research Center, have joined the Caris Precision Oncology Allianceâ"¢ (Caris POA). The Providence Swedish Cancer Institute, located in Seattle, Washington, focuses on innovative cancer diagnosis and ...

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, 2025, Caris Life Sciences (NASDAQ:CAI) announced it will present 19 breast cancer studies at the San Antonio Breast Cancer Symposium, conducted with more than 40 partner institutions through the Caris Precision Oncology Alliance. Spanning seven disease subtypes, the work showcases how Caris’ multi-omic tumor profiling, AI-driven signatures, and biomarker discovery improve recurre ...

Caris Life Sciences,?Inc. (CAI) closed the last trading session at $28.86, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.33 indicates a 32.8% upside potential.The average comprises nine short-term price targets ranging from a low of $28.00 to a high of $45.00, with a standard deviation of $4.72. While the lowest estimate indicates a decline of 3% from the curren ...

Core Insights - Caris Life Sciences announced the presentation of 19 studies on various breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, showcasing its leadership in precision oncology and AI-driven research [1][2][3] Group 1: Research and Studies - The studies cover seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male, and metastatic breast cancer [2] - Collaborating institutions include over 40 leading cancer centers, emphasizing the extensive network and collaborative efforts in advancing precision oncology [2][8] - Key presentations include a multimodal AI model for predicting breast cancer recurrence and a deep learning model for late distant recurrence risk in HR+ early breast cancer [6][11] Group 2: Company Overview and Technology - Caris Life Sciences is recognized as a pioneering company in precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data [9][10] - The company integrates whole exome and whole transcriptome sequencing with immunohistochemistry (IHC) profiling to enhance understanding of therapeutic resistance and patient outcomes [3][9] - The Caris Precision Oncology Alliance consists of 98 cancer centers and institutions, focusing on optimizing standards of care for molecular testing and improving clinical outcomes for cancer patients [8]

Accessibility StatementSkip Navigation IRVING, Texas, Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences®Â (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has joined the Caris Precision Oncology Allianceâ"¢Â (Caris POA). The Caris POA is a global network of top cancer centers and research groups that work together to advance precis ...

Core Insights - Caris Life Sciences has selected 15 physician-scientists for its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum, aimed at enhancing early-career oncologists' skills in precision medicine [1][2][4] Group 1: Program Overview - The Caris POA Fellows Forum is a competitive two-year program providing mentorship, training, and access to real-world molecular data for early-career oncologists [1][2] - Selected fellows will engage in data analysis, seminars, and mentorship sessions to deepen their expertise in molecular oncology while balancing their clinical or academic responsibilities [2][3] Group 2: Fellowship Benefits - Fellows will receive direct mentorship from Caris experts and faculty at Caris POA institutions, along with access to the CODEai database, which includes data from over 484,000 patients [5] - The program includes collaborative research projects across 97 cancer institutions and structured educational modules, virtual webinars, and lab tours [5] Group 3: Community and Networking - The Fellows Forum will facilitate periodic gatherings for community building and knowledge exchange, including tours of Caris' labs and participation in the Caris POA Summit at the ASCO Annual Meeting [3][4] - Monthly virtual workshops will be held for research updates and skill-building, reinforcing the goal of translating molecular insights into improved patient outcomes [3] Group 4: Company Background - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data [7] - The company aims to transform healthcare through comprehensive molecular profiling and has established a significant clinico-genomic database to support its initiatives [7]

Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer focused on transforming healthcare through innovative solutions [2] - The company specializes in comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, and utilizes advanced AI and machine learning algorithms to analyze complex disease data [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to enhance precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Financial Performance - Caris Life Sciences reported its third quarter 2025 financial results and increased its revenue guidance for the year [3] Upcoming Events - The company will attend several investor conferences, including Wolfe Research's 7th Annual Healthcare Conference on November 18, Citi's 2025 Global Healthcare Conference on December 3, and the 8th Annual Evercore Healthcare Conference on December 4 [4]

Financial Data and Key Metrics Changes - Total revenues increased 113% year-over-year to $216.8 million, marking a record-breaking quarter for the company [7][22] - Gross margins improved significantly to 68%, up from 43.7% in the same quarter last year [9][26] - Positive adjusted EBITDA of $51.2 million and net income of $24.3 million were reported, along with positive free cash flow of $55.3 million [10][29] - Cash on hand grew to nearly $760 million, an increase of 4.7% sequentially [10] Business Line Data and Key Metrics Changes - Elective profiling services revenues increased to $207.6 million, representing over 121% year-over-year growth [7][22] - Pharma R&D services revenues increased to $9.2 million, an increase of 18.3% year-over-year [7][22] - Clinical case volumes were slightly less than 51,000 individual profiles, reflecting an 18.2% year-over-year growth [8][11] - Average Selling Price (ASP) increased to $4,089 per profile, representing an 87% year-over-year growth [8][9] Market Data and Key Metrics Changes - The company has reached approximately 6,000 oncologists across the country, with 40% of blood cases also having a tissue case performed, up from the mid-30% range [12][70] - The penetration rate for comprehensive genomic profiling remains relatively low at about 30%, indicating significant growth opportunities [11] Company Strategy and Development Direction - The company aims to incorporate whole genome sequencing into its early detection tests, moving towards personalized disease prevention [5][6] - The focus remains on expanding the technology platform and developing new products, particularly in multi-cancer early detection [10][30] - The company is strategically assessing opportunities for expansion within marketing and sales, as well as external opportunities [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth of precision medicine and the potential for significant advancements in early detection and MRD solutions [20][21] - The company anticipates continued improvement in commercial reimbursement and expects to see a positive trend in collections from commercial payers [23][24] - Management is optimistic about achieving a full-year gross margin of 62% for 2025, up from 43.4% in 2024 [28] Other Important Information - The company has generated a cumulative total of over 1,150 peer-reviewed publications through its Precision Oncology Alliance [14] - The Achieve program remains a cornerstone of the early detection platform, with strong representation across normal and pre-malignant populations [20] Q&A Session Summary Question: What is the implied Q4 revenue and underlying gross margins excluding true-ups? - The implied Q4 revenue is expected to be in the $200 million-$210 million range, with underlying gross margins around 61% excluding true-ups [33] Question: Is the colorectal MRD data sufficient for submission to CMS? - The data is sufficient for submission, but the company is cautious about the response from CMS and has additional data ready [34][35] Question: What is the pricing strategy for early detection tests? - The company plans to adopt a premium pricing strategy for its early detection tests, reflecting the unique capabilities of its technology [81] Question: How does the company view the growth of blood-based therapy selection volumes? - The company has seen an acceleration in blood-based therapy selection volumes, with expectations for continued growth as more physicians become comfortable with the offerings [70] Question: What are the expectations for pharma R&D services in Q4? - The company expects pharma R&D services to contribute $20 million-$30 million in Q4, driven by ongoing contracts and partnerships [72][74]

Financial Performance - For the three months ended September 30, 2025, total revenue was $216.8 million, compared to $101.6 million for the same period in 2024, representing a year-over-year increase of 113%[213] - The company achieved net income of $24.3 million for the three months ended September 30, 2025, compared to a net loss of $(67.7) million in 2024[213] - For the nine months ended September 30, 2025, total revenue was $519.1 million, up from $282.3 million in 2024, marking an increase of 84%[213] - Adjusted EBITDA of $51.2 million for the three months ended September 30, 2025, compared to $(45.6) million in 2024[213] - Net income for the nine months ended September 30, 2025, was a loss of $150.0 million, an improvement from a loss of $244.9 million in the same period in 2024[284] Clinical Cases and Services - The number of clinical cases for the three months ended September 30, 2025, was 50,763, up from 42,956 in 2024, indicating a growth of 18%[215] - The number of clinical cases associated with MI Profile and Caris Assure increased from 38,409 and 4,547 cases, respectively, for the three months ended September 30, 2024, to 43,226 and 7,537 cases, respectively, for the same period in 2025, a total increase of 7,807 cases, or 18.2%[241] - The number of clinical cases associated with MI Profile increased from 107,930 to 126,160, representing a total increase of 27,797 cases or 23.4% year-over-year[261] Revenue Sources - Revenue from pharma research and development services grew by 18% year-over-year for the three months ended September 30, 2025, and 25% for the nine months ended September 30, 2025[216] - Revenue from molecular profiling services increased to $207.6 million for the three months ended September 30, 2025, from $93.8 million for the same period in 2024, representing an increase of $113.8 million, or 121.3%[239] - Molecular profiling services revenue increased to $484.6 million for the nine months ended September 30, 2025, up $229.9 million or 90.3% from $254.7 million in 2024[260] Expenses - Selling and marketing expenses were $41.3 million for the three months ended September 30, 2025, an increase of $4.5 million, or 12.3%, compared to $36.8 million for the same period in 2024[251] - General and administrative expenses increased to $52.0 million for the three months ended September 30, 2025, from $40.9 million for the same period in 2024, an increase of $11.1 million, or 27.2%[252] - Research and development expenses were $21.6 million for the three months ended September 30, 2025, compared to $27.6 million for the same period in 2024, a decrease of $6.0 million, or 21.7%[236] - Total costs and operating expenses for the three months ended September 30, 2025, were $184.2 million, compared to $162.5 million for the same period in 2024, an increase of $21.7 million, or 13.3%[236] Cash and Financing - Cash, cash equivalents, restricted cash, and marketable securities totaled $759.3 million as of September 30, 2025[213] - The company completed its IPO on June 20, 2025, raising net proceeds of $459.5 million from the sale of 23,529,412 shares at $21.00 per share[213] - Free cash flow for the nine months ended September 30, 2025, was $27.2 million, compared to a negative free cash flow of $212.4 million in the same period in 2024[285] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $661.6 million, mainly from proceeds of $528.5 million from the IPO[293] Debt and Interest - The 2023 Term Loan Agreement has an outstanding principal amount of $400.0 million, with a fixed interest rate of 10.8% as of September 30, 2025[298] - Interest income for the three months ended September 30, 2025, was $7.4 million, compared to $1.7 million for the same period in 2024, an increase of $5.6 million, or 320.5%[238] - Interest expense for the nine months ended September 30, 2025, was $45.5 million, an increase of $8.7 million or 23.8% compared to $36.8 million in 2024[277] Accounting and Revenue Recognition - The company recognized revenue in accordance with ASC Topic 606, indicating adherence to established accounting standards[306] - The company recognizes revenue from molecular profiling services upon delivery of results to physicians, identifying each sale as a single performance obligation[308] - The company recognizes pharma research and development services revenue over the period in which services are provided, using either output or input methods for revenue recognition[311] Market and Risk Factors - The company is subject to market risk from interest rate changes, but due to the short-term maturities of its investments, a 100 basis point change would not materially affect the fair market value of cash and investments[317] - The company has not engaged in foreign currency hedging transactions and does not currently face significant foreign currency risk, although this may change with international expansion[319]